HUE028725T2 - Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases - Google Patents

Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases Download PDF

Info

Publication number
HUE028725T2
HUE028725T2 HUE11720594A HUE11720594A HUE028725T2 HU E028725 T2 HUE028725 T2 HU E028725T2 HU E11720594 A HUE11720594 A HU E11720594A HU E11720594 A HUE11720594 A HU E11720594A HU E028725 T2 HUE028725 T2 HU E028725T2
Authority
HU
Hungary
Prior art keywords
compound
formula
group
nafld
nash
Prior art date
Application number
HUE11720594A
Other languages
English (en)
Hungarian (hu)
Inventor
Shridhar Narayanan
Jeyamurugan Mookkan
Jayanarayan Kulathingal
Surendran Narayanan
Gajendra Singh
Gopalan Balasubramanian
Original Assignee
Orchid Chemicals And Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals And Pharmaceuticals Ltd filed Critical Orchid Chemicals And Pharmaceuticals Ltd
Publication of HUE028725T2 publication Critical patent/HUE028725T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE11720594A 2010-07-28 2011-03-28 Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases HUE028725T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2140CH2010 2010-07-28
IN525CH2011 2011-02-23

Publications (1)

Publication Number Publication Date
HUE028725T2 true HUE028725T2 (en) 2016-12-28

Family

ID=44247871

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11720594A HUE028725T2 (en) 2010-07-28 2011-03-28 Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases

Country Status (11)

Country Link
US (1) US20140187594A1 (enExample)
EP (2) EP2987488A1 (enExample)
JP (1) JP5957452B2 (enExample)
CN (1) CN103108634B (enExample)
AU (1) AU2011284256B8 (enExample)
CA (1) CA2805245A1 (enExample)
ES (1) ES2565487T3 (enExample)
HU (1) HUE028725T2 (enExample)
PL (1) PL2598142T3 (enExample)
WO (1) WO2012014218A1 (enExample)
ZA (1) ZA201300822B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362053A4 (en) * 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN113750089B (zh) * 2021-10-13 2023-09-19 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109175A (ja) * 1994-10-07 1996-04-30 Torii Yakuhin Kk チアゾリジン−２−オンエステル誘導体
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
JP2008533122A (ja) * 2005-03-18 2008-08-21 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規なチロシン誘導体
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2008106166A2 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
JP2010520306A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−αモジュレーターとしての置換フェノキシチアゾリジンジオン
WO2009030968A1 (en) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Mao a inhibitors with a diphenyl ether-substructure.
WO2009070781A1 (en) * 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Also Published As

Publication number Publication date
JP2013532682A (ja) 2013-08-19
AU2011284256B2 (en) 2014-05-29
CN103108634A (zh) 2013-05-15
ZA201300822B (en) 2014-04-30
ES2565487T3 (es) 2016-04-05
US20140187594A1 (en) 2014-07-03
AU2011284256A1 (en) 2013-02-14
AU2011284256B8 (en) 2014-11-13
WO2012014218A1 (en) 2012-02-02
CA2805245A1 (en) 2012-02-02
EP2987488A1 (en) 2016-02-24
CN103108634B (zh) 2015-08-12
AU2011284256A8 (en) 2014-11-13
JP5957452B2 (ja) 2016-07-27
EP2598142B1 (en) 2015-12-16
EP2598142A1 (en) 2013-06-05
PL2598142T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
TWI268929B (en) Neurotrophin production/secretion promoting, thiazole and oxazole derivatives
ES3025460T3 (en) Scd inhibitor for the treatment of neurological disorders
US20230130766A1 (en) Mono and combination therapies with ulk1/2 inhibitors
CN110183431B (zh) 一类用于肝病治疗或预防的化合物
TW200918049A (en) Compounds useful as medicaments
JP7040798B2 (ja) 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
US7807663B2 (en) Therapeutic agents for diabetes
KR20250166323A (ko) 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
US7153850B2 (en) Lactam compounds and pharmaceutical use thereof
US12310967B2 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
KR102191405B1 (ko) 간 질환 예방 또는 치료용 조성물
US20260091022A1 (en) Pharmaceutical composition for treating fatty liver disease
JP7682541B2 (ja) 新規化合物およびこれを有効成分として含む呼吸器疾患の予防または治療用組成物
EP2598142B1 (en) Diphenyl ether compounds for use in the treatment of liver disorders
CN112105598B (zh) 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物
JP2008530242A (ja) 血漿中のグルコースレベル、コレステロールレベル及びトリグリセリドレベルを低下させるための５−［４−（４−（２−アミノ−２−メトキシカルボニルエチル）フェノキシ）ベンジリデン］チアゾリジン−２，４−ジオン誘導体及び関連化合物
CN110483367A (zh) 吲哚类化合物在制备药物中的用途
WO2023093700A1 (zh) 咪唑并噻唑衍生物及其制备方法与应用
CN117321050A (zh) 修饰的膜铁转运蛋白抑制剂
CN113262218A (zh) 异硫氰酸酯类化合物的用途
CN113784713A (zh) 白三烯合成抑制剂
US20220257570A1 (en) Calpain inhibitors and uses thereof for treating neurological disorders
AU2023295229A1 (en) Flavonoid compounds and methods and materials for using flavonoid compounds to treat fibrotic conditions
CN116568291A (zh) 取代的芳香族化合物及其药物组合物